s
Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata
30-05-2024, 10:06
LONDON, May 30, 2024 /PRNewswire/ — Soterios Pharma, a privately held clinical-stage pharmaceutical company, today announced positive topline results from its randomised, placebo-controlled, multi-dose Phase II trial evaluating STS-01 as a treatment for mild / moderate AA. At 24 weeks, 75.9% of patients treated with once-daily topical dosing of 1% STS-01 met the primary efficacy […] L'articolo Soterios Pharma Announces Positive Topline Results from Phase II Study of STS-01 in the Treatment of Mild / Moderate Alopecia Areata proviene da La Ragione.
CONTINUA A LEGGERE
19
0
0
Guarda anche
La Ragione
Ieri, 21:43
Manovra, Tajani “Extraprofitto incomprensibile, concetto extraterrestre”
La Ragione
Ieri, 19:43
Confesercenti “Tetti agli affitti per le attività di prossimità”
La Ragione
Ieri, 19:43
Scontri a Roma tra i manifestanti pro Palestina e le forze dell’ordine
La Ragione
Ieri, 18:52
Alimentazione, esperti: “Con esercizio fisico pilastri longevità sana”
La Ragione
Ieri, 18:12